Influenza Viral Challenge Study of CC-42344 in Healthy Participants

Launched by COCRYSTAL PHARMA, INC. · Nov 29, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new medication called CC-42344 to see how well it works in healthy adults against the influenza A virus, commonly known as the flu. Participants will be given either CC-42344 or a placebo (a treatment that has no active ingredients) for five days after being exposed to the flu virus. During the study, researchers will collect nasal samples to measure how much virus is present and will also check for any side effects and how the body processes the medication.

To join this study, participants need to be healthy adults aged 18 to 65, weigh at least 50 kg (about 110 pounds), and meet certain health criteria. They should not have any recent illnesses or vaccinations that could affect the results. Throughout the trial, participants will not know whether they are receiving the actual medication or the placebo, which helps ensure the study’s results are reliable. This study is currently recruiting participants who fit the eligibility criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Healthy adults
• • Body weight ≥50 kg
• • Body mass index ≥18 kg/m2 and ≤35 kg/m2
• • Serology results consistent with susceptibility to challenge virus infection
• Exclusion Criteria:
• • History of or current significant medical condition
• • Upper or lower respiratory tract infection within 4 weeks
• • Vaccination within 4 weeks